European Medicines Agency (2013) Surface coatings: general issues for consideration regarding
parenteral administration of coated nanomedicine products.https://www.ema.europa.eu/en/
surface-coatings-general-issues-consideration-regarding-parenteral-administration-coated.
Accessed 14 Apr 2019
European Medicines Agency (2014a) Data requirements for intravenous liposomal products devel-
oped with reference to an innovator liposomal product. https://www.ema.europa.eu/en/data-
requirements-intravenous-liposomal-products-developed-reference-innovator-liposomal-prod
uct-0. Accessed 16 May 2020
European Medicines Agency (2014b) Development of block-copolymer-micelle medicinal
products. https://www.ema.europa.eu/en/development-block-copolymer-micelle-medicinal-
products. Accessed 17 Apr 2019
European Medicines Agency (2015) Data requirements for intravenous iron-based nano-colloidal
products developed with reference to an innovator medicinal product. https://www.ema.europa.
eu/en/data-requirements-intravenous-iron-based-nano-colloidal-products-developed-reference-
innovator. Accessed 16 Apr 2019
Farahani BV, Behbahani R, Javadi N (2016) Functionalized multi walled carbon nanotubes as a
carrier for doxorubicin: drug adsorption study and statistical optimization of drug loading by
factorial design methodology. J Braz Chem Soc 27(4):694–605
FDA (2017) Drug products, including biological products, that contain nanomaterials. https://www.
fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM588857.pdf. Accessed 6 Apr 2019
Gajera BY, Shah DA, Dave RH (2018) Investigating a novel hot melt extrusion-based drying
technique to solidify an amorphous nanosuspension using design of experiment methodology.
AAPS PharmSciTech 19(8):3778–3790
Gajra B, Dalwadi C, Patel R (2015) Formulation and optimization of itraconazole polymeric lipid
hybrid nanoparticles (Lipomer) using Box Behnken design. DARU J Pharm Sci 23(1):1–3
Garala KC, Shinde AJ, More HN (2009) Solubility enhancement of aceclofenac using dendrimer.
Res J Pharm Dosage Form Technol 1(2):94–96
Garg BJ, Garg NK, Beg S, Singh B, Katare OP (2016a) Nanosized ethosomes-based hydrogel
formulations of methoxsalen for enhanced topical delivery against vitiligo: formulation optimi-
zation, in vitro evaluation and preclinical assessment. J Drug Target 24(3):233–246
Garg NK, Singh B, Jain A, Nirbhavane P, Sharma R, Tyagi RK et al (2016b) Fucose decorated
solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics.
Colloids Surf B Biointerfaces 146:114–126
Garg NK, Sharma G, Singh B, Nirbhavane P, Tyagi RK, Shukla R et al (2017a) Quality by design
(QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): an
improved dermatokinetic profile for inflammatory disorder(s). Int J Pharm 517(12):413–431
Garg V, Kaur P, Singh SK, Kumar B, Bawa P, Gulati M et al (2017b) Solid self-nanoemulsifying
drug delivery systems for oral delivery of polypeptide-k: formulation, optimization, in-vitro and
in-vivo antidiabetic evaluation. Eur J Pharm Biopharm 109:297–315
Garg B, Beg S, Kaur R, Kumar R, Katare OP, Singh B (2018) Long-chain triglycerides-based self-
nanoemulsifying oily formulations (SNEOFs) of darunavir with improved lymphatic targeting
potential. J Drug Target 26(3):252–266
Ghosh I, Schenck D, Bose S, Liu F, Motto M (2013) Identification of critical process parameters
and its interplay with nanosuspension formulation prepared by top down media milling tech-
nology—a QbD perspective. Pharm Dev Technol 18(3):719–729
Godbole MD, Sabale PM, Mathur VB (2020) Development of lamivudine liposomes by three-level
factorial design approach for optimum entrapment and enhancing tissue targeting. J
Microencapsul 37:1–14
González-Rodríguez ML, Mouram I, Cózar-Bernal MJ, Villasmil S, Rabasco AM (2012) Applying
the Taguchi method to optimize sumatriptan succinate niosomes as drug carriers for skin
delivery. J Pharm Sci 101(10):3845–3863
18
QbD-Steered Systematic Development of Drug Delivery Nanoconstructs:. . .
345